ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1421

Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans

Luis Palomino1, Angelo Gaffo2, Sebastian Sattui3 and Dongmei Sun2, 1University of Alabama at Birmingham Hospital, Birmingham, AL 2University of Alabama at Birmingham, Birmingham, AL, 3Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2020

Keywords: ANCA, ANCA associated vasculitis, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Vasculitis – ANCA-Associated Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical presentation, clinical features, and prognosis of AAV in African Americans (AAs) have not been well described. The objective of this study was to compare the clinical features and outcomes at time of diagnosis of AA patients with AAV to Caucasian patients. Our hypothesis was that AA patients with AAV present with a higher frequency of MPA, greater disease severity, and experience higher mortality compared to Caucasian patients.  

Methods: We conducted a retrospective chart review of patients with ICD-9-CM and ICD-10 codes used for AAV (446.0, 446.4, 447.6 and M31.3, 31.7, M30.1, I77.6, M31.9, M31.8) between 1/2003 to 12/2018. Diagnosis was confirmed by two reviewers (one rheumatologist), and in case of discordance, a third reviewer was involved (rheumatologist). Race was verified through chart review. AA cases were randomly matched by year of diagnosis (± 4 years) in a 1:2 ratio with Caucasian controls. Demographics, clinical and laboratory features, disease activity and prognosis were abstracted by chart review using the Birmingham Vasculitis Activity Score (BVAS) 3 and Five-Factor Score (FFS). T-test, Chi-square and Fisher exact test were used for statistical analysis, when appropriate.  

Results: 548 AA patients were identified using diagnostic codes. 56 AA patients were confirmed to have AAV via chart review but only 32 of these cases were confirmed using diagnostic criteria. We matched 64 similarly confirmed Caucasian controls. Compared to Caucasians, AA patients with AAV were younger (47.5 years [IQR 32.5] vs 61.0 years [IQR 19.5], p = 0.001). No other clinical or laboratory features were different compared to Caucasians (Table 1). In addition, we found no difference in frequency of GPA, MPA, or EGPA phenotypes between AA and Caucasians. Younger age at presentation was observed among AAs with GPA (35 [IQR  24] vs 55 [IQR 20), p = 0.006) and MPA (55.5 [IQR 20] vs 65.0 [IQR 13], p = 0.02) (Table 2).  Compared with Caucasians, the proportion of women with GPA was higher among AAs (82.3% vs 47.8%, p = 0.008) but the proportion of AA men with MPA was higher (53.3% vs 15%, p = 0.03) (Table 2). There was no difference in disease activity, severity of manifestations or mortality.

Conclusion: In this single center retrospective study, AA patients with AAV presented at a younger age compared with Caucasians. No differences in mortality rates, clinical phenotypes, clinical and laboratory features, disease activity, prognostic scores, or mortality were observed.

Table 1

Table 2


Disclosure: L. Palomino, None; A. Gaffo, Amgen, 1; S. Sattui, None; D. Sun, None.

To cite this abstract in AMA style:

Palomino L, Gaffo A, Sattui S, Sun D. Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-features-disease-activity-and-prognosis-of-anca-associated-vasculitis-in-us-african-americans/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-disease-activity-and-prognosis-of-anca-associated-vasculitis-in-us-african-americans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology